Treatment Patterns in Patients with Incident Parkinson’s Disease in the United States-Reference-Cited by-同舟云学术

Treatment Patterns in Patients with Incident Parkinson’s Disease in the United States

Published:2019-10-11 Issue:4 Volume:9 Page:749-759
ISSN:1877-7171
Container-title:Journal of Parkinson's Disease
language:
Short-container-title:JPD

Author:

Houghton Richard¹,Boess Frank²,Verselis Lynne³,Ding Yingjie⁴,Freitas Rita¹,Constantinovici Niculae¹,Ong Rose¹

Affiliation:

1. Product Development Personalized Health Care, F. Hoffmann-La Roche Ltd., Basel, Switzerland

2. Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland

3. Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Area, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd., New York NY, USA

4. Genesis Research, Hoboken NJ, USA

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Clinical Neurology

Reference32 articles.

1. Epidemiology of Parkinson’s disease;de Lau;Lancet Neurol,2006

2. Alzheimer’s disease and Parkinson’s disease;Nussbaum;N Engl J Med,2003

3. MDS research criteria for prodromal Parkinson’s disease;Berg;Mov Disord,2015

4. Parkinson’s disease therapeutics: New developments and challenges since the introduction of levodopa;Smith;Neuropsychopharmacology,2012

5. Toward neuroprotective treatments of Parkinson’s disease;Kim;Proc Natl Acad Sci U S A,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson’s Disease;ClinicoEconomics and Outcomes Research;2023-08

2. Dopaminergic treatment strategies for people with Parkinson’s disease in Europe: a retrospective analysis of PRISM trial data;Neurological Sciences;2023-06-13

3. Tiempo hasta la modificación de la terapia antiparkinsoniana en un grupo de pacientes de Colombia;Revista de Neurología;2023

4. Co-administration of Nanowired DL-3-n-Butylphthalide (DL-NBP) Together with Mesenchymal Stem Cells, Monoclonal Antibodies to Alpha Synuclein and TDP-43 (TAR DNA-Binding Protein 43) Enhance Superior Neuroprotection in Parkinson’s Disease Following Concussive Head Injury;Advances in Neurobiology;2023

5. Treatment initiation for parkinson’s disease in Australia 2013–2018: a nation-wide study;BMC Geriatrics;2022-06-03